Novel Adjuvant Therapy with Zinc Supplementation in Neonatal Respiratory Distress Syndrome
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Neonatal respiratory distress syndrome (RDS) is a common dangerous chest problem that is caused by a lack of surfactant.
AIM: The aim of this study was to show the role of zinc as an adjuvant anti-inflammatory therapy in neonatal RDS.
OBJECTIVE: To study the effect of zinc supplementation in cases of neonatal RDS.
METHODS: A prospective randomized controlled trial (RCT) study was done on 90 neonates suffering from respiratory distress (RD) who had been diagnosed as RDS. The included neonates were classified into two groups: group 1, which received Zinc (Zn) supplementation, and group 2, which received a placebo. Down score, grades of RDS Malondialdehyde (MDA), Superoxide Dismutase (SOD) andInterleukin-8 (IL-8) were estimated on the 1st and 5th day in the presence of incubators.
RESULTS: There were statistically significant differences (SSD) in grades of RDS, Down score, MDA, SOD and IL-8 on the 5th day between group 1 and 2(p = 0.001), and between 1st and 5th day in group 1 (p = 0.001) in the presence of an incubator. There was an SSD between groups 1 and 2 in the duration of hospitalization (p = 0.001) and the number of cases that needed mechanical ventilation (MV) (p = 0.049).
CONCLUSION: Zn supplementation is associated with clinical and laboratory improvement in cases of neonatal RDS.
RECOMMENDATION: Zn supplementation for RDS neonates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders drug targets - 21(2021), 12 vom: 03., Seite 2253-2259 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Elfarargy, Mohamed Shawky [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Completed 04.04.2022 Date Revised 05.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871530321666210729113515 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328702463 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328702463 | ||
| 003 | DE-627 | ||
| 005 | 20231225203512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871530321666210729113515 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328702463 | ||
| 035 | |a (NLM)34325645 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Elfarargy, Mohamed Shawky |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel Adjuvant Therapy with Zinc Supplementation in Neonatal Respiratory Distress Syndrome |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2022 | ||
| 500 | |a Date Revised 05.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Neonatal respiratory distress syndrome (RDS) is a common dangerous chest problem that is caused by a lack of surfactant | ||
| 520 | |a AIM: The aim of this study was to show the role of zinc as an adjuvant anti-inflammatory therapy in neonatal RDS | ||
| 520 | |a OBJECTIVE: To study the effect of zinc supplementation in cases of neonatal RDS | ||
| 520 | |a METHODS: A prospective randomized controlled trial (RCT) study was done on 90 neonates suffering from respiratory distress (RD) who had been diagnosed as RDS. The included neonates were classified into two groups: group 1, which received Zinc (Zn) supplementation, and group 2, which received a placebo. Down score, grades of RDS Malondialdehyde (MDA), Superoxide Dismutase (SOD) andInterleukin-8 (IL-8) were estimated on the 1st and 5th day in the presence of incubators | ||
| 520 | |a RESULTS: There were statistically significant differences (SSD) in grades of RDS, Down score, MDA, SOD and IL-8 on the 5th day between group 1 and 2(p = 0.001), and between 1st and 5th day in group 1 (p = 0.001) in the presence of an incubator. There was an SSD between groups 1 and 2 in the duration of hospitalization (p = 0.001) and the number of cases that needed mechanical ventilation (MV) (p = 0.049) | ||
| 520 | |a CONCLUSION: Zn supplementation is associated with clinical and laboratory improvement in cases of neonatal RDS | ||
| 520 | |a RECOMMENDATION: Zn supplementation for RDS neonates | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Neonate | |
| 650 | 4 | |a Zinc | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a respiratory distress | |
| 650 | 4 | |a supplementation | |
| 650 | 4 | |a syndrome. | |
| 650 | 4 | |a therapy | |
| 650 | 7 | |a Pulmonary Surfactants |2 NLM | |
| 650 | 7 | |a Zinc |2 NLM | |
| 650 | 7 | |a J41CSQ7QDS |2 NLM | |
| 700 | 1 | |a Al-Ashmawy, Ghada M |e verfasserin |4 aut | |
| 700 | 1 | |a Abu-Risha, Sally |e verfasserin |4 aut | |
| 700 | 1 | |a Khattab, Haidy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders drug targets |d 2006 |g 21(2021), 12 vom: 03., Seite 2253-2259 |w (DE-627)NLM161976174 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:12 |g day:03 |g pages:2253-2259 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871530321666210729113515 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 12 |b 03 |h 2253-2259 | ||